Valuation: LB Pharmaceuticals Inc

Market Cap 915M 801M 740M 691M 1.3B 86.54B 1.33B 8.9B 3.44B 42.69B 3.44B 3.36B 148B P/E 2026 *
-9x
P/E 2027 * -7.29x
Enterprise Value 626M 548M 506M 473M 890M 59.19B 910M 6.09B 2.35B 29.2B 2.35B 2.3B 101B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day-0.05%
1 week+6.70%
Current month+13.94%
1 month+13.94%
3 months+37.08%
6 months+48.93%
Current year+43.17%
1 week 29.65
Extreme 29.65
32.18
1 month 26.37
Extreme 26.37
32.18
Current year 18.43
Extreme 18.43
33.47
1 year 13.36
Extreme 13.36
33.47
3 years 13.36
Extreme 13.36
33.47
5 years 13.36
Extreme 13.36
33.47
10 years 13.36
Extreme 13.36
33.47
Manager TitleAgeSince
Chief Executive Officer 53 2024-11-18
Director of Finance/CFO 55 2016-02-29
Chief Tech/Sci/R&D Officer 59 2025-01-31
Director TitleAgeSince
Director/Board Member 76 2019-06-30
Director/Board Member 53 2023-07-31
Director/Board Member 53 2024-11-18
Date Insider Type Main position Quantity % Market Cap.
06-02Free

Director

10,000 0.0446%
06-02Free

Chairman

10,000 0.0446%
06-02Free

Director

10,000 0.0446%
Change 5-day change 1-year change 3-year change Capi.($)
-0.05%+6.70% - - 915M
+0.13%-1.33%+67.18%+121.93% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+2.50%+3.68%-12.17%-12.61% 23.07B
+0.65%+5.57%+3.43%+412.28% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+3.81%+30.68%-32.21% 15.94B
-0.55%+6.02%+23.52%+187.13% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +3.14%+6.79%+48.38%+136.50% 22.72B
Weighted average by Cap. +3.28%+7.61%+54.66%+127.63%

Financials

2026 *2027 *
Net sales - -
Net income -105M -92.24M -85.15M -79.51M -150M -9.96B -153M -1.02B -396M -4.91B -396M -387M -17.06B -162M -142M -131M -122M -230M -15.31B -235M -1.57B -608M -7.55B -608M -595M -26.22B
Net Debt -289M -253M -234M -218M -411M -27.35B -420M -2.81B -1.09B -13.49B -1.09B -1.06B -46.85B -450M -394M -364M -340M -640M -42.55B -654M -4.38B -1.69B -20.99B -1.69B -1.65B -72.89B
Logo LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Employees
35
Date Price Change Volume
26-06-29 US$31.87 -0.16% 240,979
26-06-26 US$31.92 +2.97% 1,413,712
26-06-25 US$31.00 +1.71% 213,094
26-06-24 US$30.48 -0.39% 295,027
26-06-23 US$30.60 +2.44% 824,513
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
31.92USD
Average target price
45.00USD
Spread / Average Target
+40.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LBRX Stock